600535.SH
天士力
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 14.82
−1.00%Year over year
Reported trailing growth
- Revenue
- -1.9%
- EBITDA
- —
- EBIT
- +25.9%
- EPS
- +19.7%
- Free cash flow
- +45.3%
- Operating cash flow
- +13.2%
Forward estimates
Based on analyst estimates
- Revenue
- -3.3%
- EBITDA
- -68.1%
- EPS
- +78.6%
Three-year CAGR
- Revenue
- -1.6%
- EBITDA
- +84.7%
- EBIT
- +5.0%
- Net income
- +1.6%
- EPS
- +1.4%
- Free cash flow
- -17.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026